Claims

1. The use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject infected with HIV, wherein the formulation is to be administered intermittently at a time interval that is in the range of one week to one year.

2. The use according to claim 1 wherein the formulation is to be administered at a time interval that is in the range of one week to one month.

3. The use according to claim 1 wherein the formulation is to be administered at a time interval that is in the range of one month to three months.

4. The use according to claim 1 wherein the formulation is to be administered at a time interval that is in the range of three months to six months.

5. The use according to claim 1 wherein the formulation is to be administered once every two weeks.

6. The use according to claim 1 wherein the formulation is to be administered once every month.

7. The use according to claim 1 wherein the effective amount of TMC278 in the parenteral formulation is selected such that the blood plasma concentration of TMC278 is kept during a prolonged period of time above a minimum blood plasma level that is the lowest blood plasma level that causes the HIV inhibitor to be effective in suppressing HIV.

8. The use according to claim 4 wherein the blood plasma level is kept at a level equal to or above about 20 ng/ml.

9. The use according to any of claims 1-5, wherein the formulation is to be administered subcutaneously or intramusculary.

Claims:

1. The use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of HIV, wherein the medicament is to be administered intermittently by subscutaneous or intramuscular administration at a time interval that is in the range of two weeks to one year.

2. The use according to claim 1 wherein the medicament is to be administered at a time interval that is in the range of two weeks to four weeks.

3. The use according to claim 1 wherein the medicament is to be administered at a time interval that is in the range of one month to three months.

4. The use according to claim 1 wherein the medicament is to be administered at a time interval that is in the range of three months to six months.

5. The use according to claim 1 wherein the medicament is to be administered once every two weeks.

6. The use according to claim 1 wherein the medicament is to be administered once every month.

7. The use according to claim 1 wherein the medicament is to be administered once every two months.

8. The use according to claim 1 wherein the medicament is to be administered once every three months.

9. The use according to claim 1 wherein the effective amount of TMC278 in the parenteral formulation is selected such that the blood plasma concentration of TMC278 is kept during a prolonged period of time above a minimum blood plasma level that is the lowest blood plasma level that causes the HIV inhibitor to be effective in suppressing HIV.

10. The use according to claim 9 wherein the blood plasma level is kept at a level equal to or above 20 ng/ml.

11. The use according to any one of claims 1 to 8 wherein the dose of TMC278 to be administered each time is calculated on a basis of 0.5 mg/day to 50 mg/day.

12. The use according to claim 11 wherein the dose of TMC278 to be administered each time is calculated on a basis of 1 mg/day to 20 mg/day.

13. The use according to claim 12 wherein the dose of TMC278 to be administered each time is calculated on a basis of 1 mg/day to 10 mg/day.

14. The use according to claim 13 wherein the dose of TMC278 to be administered each time is calculated on a basis of 3 mg/day to 7 mg/day.

15. The use according to any one of claims 3, 4, 6, 7 or 8 wherein the monthly dose of TMC278 ranges from 30 mg to 600 mg.

16. The use according to claim 15 wherein the monthly dose of TMC278 ranges from 30 mg to 300 mg.

17. The use according to claim 16 wherien the monthly dose of TMC278 ranges from 90 mg to 210 mg.

18. The use according to claim 17 wherein the monthly dose of TMC278 is 150 mg.

19. The use according to any one of the preceding claims wherein the formulation further comprises a solubilizer or surfactant.

20. The use according to claim 19 wherein the surfactant is selected from poloxamers,

α-tocopheryl polyethylene glycol succinates, polyoxyethylene sorbitan fatty acid esters and polyethylene glycols.

21. The use according to any one of the preceding claims wherein TMC278 is in base-form.

22. The use according to any one of the preceding claims wherein the TMC278 occurs in its E-isomeric form.

23. A parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for use in the treatment of HIV, wherein the formulation is to be administered intermittently by subscutaneous or intramuscular administration at a time interval that is in the range of two weeks to one year.

24. A parenteral formulation for use according to claim 23 wherein the formulation is to be administered once every month, once every two months or once every three months.

25. A parenteral formulation for use according to claim 23 or 24 wherein the dose of TMC278 to be administered each time is calculated on a basis of 0.5 mg/day to 50 mg/day or is calculated on a basis of 1 mg/day to 20 mg/day or is calculated on a basis of 1 mg/day to 10 mg/day or is calculated on a basis of 3 mg/day to 7 mg/day.

26. A parenteral formulation for use according to claim 24 wherein the monthly dose of TMC278 ranges from 30 mg to 600 mg or ranges from 30 mg to 300 mg or ranges from 90 mg to 210 mg or is 150 mg.

27. A parenteral formulation for use according to any one of claims 23 to 26 wherein TMC278 is in base-form.

28. A parenteral formulation for use according to any one of claims 23 to 27 wherein the TMC278 occurs in its E-isomeric form.